CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment.
LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤组织中的三级淋巴结构(TLSs)促进免疫细胞迁移和细胞毒性,从而有利于生存和免疫治疗中的良好应答。在此,我们通过检索癌症患者的 RNA 测序(RNA-seq)数据,观察到肿瘤坏死因子超家族成员 14(LIGHT)表达与 TLS 特征基因高度相关,这些基因均是免疫细胞积聚和更好预后的标志物,提示 LIGHT 在重建高度免疫浸润的肿瘤微环境中的潜力。
因此,共表达 LIGHT 的CAR-T(LIGHT CAR-T)细胞不仅表现出增强的细胞毒性和细胞因子产生,还提高了周围细胞 CCL19 和 CCL21 的表达。并且 LIGHT CAR-T 细胞的上清液以旁分泌方式促进 T 细胞迁移。
此外,在免疫缺陷 NSG 小鼠中,与常规 CAR-T 细胞相比,LIGHT CAR-T 细胞表现出更优的抗肿瘤疗效和改善的浸润。相应地,在 C57BL/6 同系肿瘤小鼠模型中,小鼠 LIGHT-OT-1 T 细胞使肿瘤血管正常化并强化了瘤内淋巴结构,提示 LIGHT CAR-T 在临床应用中的潜力。
综上所述,我们的数据揭示了一种直接策略,即通过 LIGHT 表达重定向 TLSs 来优化 CAR-T 细胞的迁移和细胞毒性,这具有扩大和优化 CAR-T 疗法在实体瘤中应用的巨大潜力。
Tertiary lymphoid structures (TLSs) in tumor tissues facilitate immune cell trafficking and cytotoxicity, which benefits survival and favorable responses in immune therapy.
Here, we observed a high correlation of tumor necrosis factor superfamily member 14 (LIGHT) expression with TLS signature genes, which are all markers for immune cell accumulation and better prognosis, through retrieving RNA sequencing (RNA-seq) data from patients with cancer, suggesting the potential of LIGHT in reconstituting a high immune-infiltrated tumor microenvironment.
Accordingly, LIGHT co-expressed chimeric antigen receptor T (LIGHT CAR-T) cells not only showed enhanced cytotoxicity and cytokine production but also improved CCL19 and CCL21 expression by surrounding cells. And the supernatant of LIGHT CAR-T cells promoted T cell migration in a paracrine manner.
Furthermore, LIGHT CAR-T cells showed superior anti-tumor efficacy and improved infiltration in comparison with conventional CAR-T cells in immunodeficient NSG mice. Accordingly, murine LIGHT-OT-1 T cells normalized tumor blood vessels and enforced intratumoral lymphoid structures in C57BL/6 syngeneic tumor mouse models, implying the potential of LIGHT CAR-T in clinical application.
Taken together, our data revealed a straightforward strategy to optimize trafficking and cytotoxicity of CAR-T cells by redirecting TLSs through LIGHT expression, which has great potential to expand and optimize the application of CAR-T therapy in solid tumors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。